CoatesA., AbrahamS., KayeS.B.: On the reciving end patients perception of the side effects of cancer chemotherapy.Eur J Cancer Clin Oncol,19: 203, 1983.
2.
SchnellF.M.: Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control.Oncologist,8: 187–198, 2003.
3.
GrunbergS.M., HeskethP.J.: Control of chemotherapy-induced emesis.N Engl J Med,329: 1790–1796, 1993.
4.
Gralla RJ, Osoba D, Kris MG et al for the American Society of Clinical Oncology:Recommendations for the use of antiemetics. Evidence-based, clinical practice guidelines.J Clin Oncol,17: 2971–2994, 1999.
5.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis:results of the Perugia Consensus Conference.Ann Oncol,9: 811–819, 1998.
6.
DeVaneC.L., SubstanceP.: A new era, a new role.Pharmacotherapy,21: 1061–1069, 2001.
7.
KramerM.S., CutlerN., FeighnerJ.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors.Science,281: 1640–1645, 1998.
8.
HeskethP.J.: Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.Support Care Cancer,9: 350–354, 2001.
9.
TattersallF.D., RycroftW., FrancisB.: Tachykinin NKl receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.Neuropharmacology,35: 1121–1129, 1996.
10.
PistersK.M., KrisM.G.: Treatment-related nausea and vomiting. In: Principles and practice of supportive oncology,BergerA., PortenoyR.K., WeissmanJ.E. (Eds), pp 165–177, Lippincott-Raven, Philadelphia, PA, 1998.
11.
KrisM.G., GrallaR.J., ClarkR.A.: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.J Clin Oncol,3: 1379–1384, 1985.
12.
TavorathR., HeskethP.J.: Drug treatment of chemotherapy-induced delayed emesis.Drugs,52: 639–648, 1996.
13.
HeskethP.J., Van BelleS., AaproM.: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.Eur J Cancer,39: 1074–1080, 2003.
14.
CocquytV., Van BelleS., ReinhardtR.R.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.Eur J Cancer,37: 835–842, 2001.
15.
CamposD., PereiraJ.R., ReinhardtR.R.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.J Clin Oncol,19: 1759–1767, 2001.
16.
Merck & Co Inc:EMEND® (aprepitant) capsules: prescribing information. USA (online). Available from URL: http://www.merck.com
17.
TattersallF.D., RycroftW., CumberbatchM.: The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.Neuropharmacology,39: 652–653, 2000.
18.
DandoT.M., PerryC.M.: Aprepitant. A review of its use in the prevention of chemotherapy-induced nausea and vomiting.Drugs,64: 777–794, 2004.
19.
Van BelleS., LichtnitserM.R., NavariR.M.: Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonist.Cancer,94: 3032–3041, 2002.
20.
NavariR., ReinhardtR., GrallaR.J.: Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist.N Engl J Med,340: 190–195, 1999.
21.
De WitR., HerrstedtJ., RapoportB.: The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.Eur J Cancer,40: 403–410, 2004.
22.
ChawlaS.P., GrunbergS.M., GrallaR.J.: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Cancer,97: 2290–2300, 2003.
23.
MartinA.R., PearsonJ.D., CaiB.: Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis.Qual Life Res,9: 18, 2000.
24.
GrallaR.J., WarrD.G., CaridesA.D.: Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials.Proc ASCO,23: abstr 8137, 2004.
25.
HeskethP.J., GrunbergS.M., GrallaR.J.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 study group.J Clin Oncol,21: 4112–4119, 2003.
26.
Poli-BigelliS., Rodrigues-PereiraJ., CaridesA.D.: Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America.Cancer,97: 3090–3098, 2003.
